Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

CVS Health

General Dynamics

Lockheed Martin

Burry's Scion Asset Management swapped out four of its six US stocks last quarter, helping to boost its portfolio's value by 78%.

'Big Short' investor Michael Burry discloses new bets on Bristol-Myers Squibb and General Dynamics — and reveals he sold CVS Health and Lockheed Martin

AbbVie

Amgen

Sanofi

Vertex Pharmaceuticals

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Will the Rally of These 5 Big Drugmakers Continue in 2022?

BASF SE

Deutsche Telekom AG

3 Companies With Safe Yield And Significant Upside

Bath and Body Works

DuPont de Nemours

PepsiCo

Twitter

There are several ways that a company can return wealth to its shareholders. Price appreciation and dividends are the two most common ways, but there are other ways a company can introduce returns to buyers.

6 Companies That Recently Announced Large Buybacks

Abbott Labs

Alnylam Pharmaceuticals

Cerner

Regeneron Pharmaceuticals

Stryker

Waters

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

The Vanguard Health Care Fund's Top 5 Trades

Bristol Myers Squibb BMY, -0.45% said Wednesday it has entered a $5 billion accelerated share buyback program with Morgan Stanley, Barclays Bank, Citibank and JP Morgan. The deal is part of the drug company's $15 billion share buyback program and it will have about $10.2 billion remaining in the authorization once the accelerated deal closes.

Bristol Myers Squibb announces $5 billion accelerated share buyback program

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements

Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements

Eli Lilly

Merck

Should investors be putting these pharmaceutical stocks on their watchlists?

4 Pharmaceutical Stocks To Watch In February 2022￼

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BristolMyersSquibb--Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.

Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.

Bristol-Myers Squibb continues to deliver excellent results, making the stock one of the best deep value picks in the biopharma sector. Management expects solid growth rates through 2029 thanks to strong pipeline despite patent losses from Revlimid and Pomalyst.

Bristol-Myers Squibb: Strong Q4 Results Strengthen The Bull Case

Bristol-Myers reported its Q4 and full-year financial results on Friday.

Bristol-Myers Q4 results beat Wall Street estimates

Bristol-Myers Squibb Co (BMY) CEO Giovanni Caforio on Q4 2021 Results - Earnings Call Transcript

Bristol-Myers (BMY) earnings match estimates in the fourth quarter of 2021, while sales beat the same on the back of Eliquis and Opdivo.

Bristol-Myers (BMY) Q4 Earnings Meet Estimates, Sales Beat

Shares of Bristol-Myers Squibb Co (NYSE: BMY) jumped 3.0% on Friday morning after the pharmaceutical giant reported its Q4 results and offered guidance for fiscal 2022. Q4 financial performance Bristol-Myers earned $2.4 billion in the fourth quarter that translates to $1.07 per share.

Bristol-Myers Q4 results are out: this is what the report tells us

Bristol Myers (BMY) delivered earnings and revenue surprises of 0% and 0.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q4 Earnings Meet Estimates

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021

ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021

Bristol Myers Squibb & Co  BMY has posted Q4 revenues of $11.98 billion, an increase of 8%, missing the consensus estimate of $12.08 billion.  Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Bristol Myers Q4 Revenue, FY22 Sales Outlook Lag Consensus

Shares of Bristol Myers Squibb Co. BMY, -1.13% were up 1.1% in premarket trading on Friday after the drug maker beat earnings expectations for the final quarter of the year. Bristol had earnings of $2.4 billion, or $1.07 per share, in the fourth quarter of 2021, after a loss of $10.0 billion, or $4.45 per share, in the same quarter a year ago.

Bristol's stock gains after beating earnings estimates for the fourth quarter

Drugmaker Bristol Myers Squibb Co on Friday posted slightly better than expected fourth-quarter earnings on strong sales of blood thinner Eliquis and cancer drug Opdivo.

Bristol Myers posts slightly better-than-expected 4th-qtr results

Amazon

Air Products and Chemicals

Pinterest

Snap

Some of the stocks that may grab inve3stor focus today are: Wall Street expects Bristol-Myers Squibb Company BMY to report quarterly earnings at $1.80 per share on revenue of $12.08 billion after the closing bell. Bristol-Myers Squibb shares rose 0.4% to $64.30 in pre-market trading.

5 Stocks To Watch For February 4, 2022

Let us take a look at three biotech/pharma companies ??? BMY, REGN and SNY?

Drug/Biotech Stock Q4 Earnings Due on Feb 4: BMY, REGN & SNY

Pfizer

A bear market isn't going to stop these stocks from delivering a steadily growing stream of dividend payments.

3 Pharmaceutical Stocks With Dividend Yields of 2.9% or Better

Bristol-Myers' (BMY) Q4 earnings might have gained from strong demand for its multiple myeloma drug, Revlimid. Operating expenses might have jumped on costs associated with the broader portfolio.

Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store?

General Motors

Teva Pharmaceutical

Bristol Myers Squibb, General Motors, and Teva Pharmaceutical Industries are three dirt cheap Buffett stocks worth buying right now.

Are Warren Buffett's 3 Cheapest Stocks Screaming Buys?

Gilead Sciences

Biotech's blue bloods are the best bets in the space right now.

News for Bristol-Myers Stock (BMY)